Yohei Doi, MD, PhD

Fujita Health University, Japan

Disclosure(s): bioMerieux: Lecture fees; Entasis: Grant/Research Support; Fujifilm: Advisor/Consultant; Gilead Sciences: Advisor/Consultant; GSK: Advisor/Consultant; KANTO CHEMICAL CO.,INC.: Grant/Research Support, Patent for genotyping kit; MeijiSeika Pharma: Advisor/Consultant; Moderna: Advisor/Consultant; MSD: Lecture fees; Pfizer: Advisor/Consultant; Shionogi & Co., Ltd.: Grant/Research Support, Lecture fees

Poster(s):

• (P-1826) Genomic Epidemiology and Clinical Characteristics of Stenotrophomonas maltophilia at an academic medical center
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT

• (P-1828) Virulence-Associated Genes of Carbapenem-Resistant Klebsiella pneumoniae isolates in a National Government Referral Center in the Philippines
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT

• (P-2021) How Have COVID-19 Treatment Guidelines and the Scientific Evidence Evolved throughout the Pandemic and Endemic Eras?
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT

• (P-2044) Analysis of Post COVID-19 Condition After Ensitrelvir Treatment in Asymptomatic or Mild-Symptoms Only Patients in the SCORPIO Phase2b/3 Study
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT

• (P-2163) Inconsistent identification of Corynebacterium species by MALDI-TOF MS and molecular characteristics of Corynebacterium jeikeium complex isolates causing invasive infections in Japan.
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT